biostudies-literatureKumpunya SRatchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn UniversityThailand Science Research and Innovation Fund Chulalongkorn University13908https://www.ebi.ac.uk/biostudies/studies/S-EPMC12015545biostudies-literatureUnknown15(1)<h4>Background</h4>Antibiotic treatment contributes to gut microbiota dysbiosis. Previous studies have shown that fecal microbiota transplantation (FMT), fecal filtrate (FF), and activated charcoal (AC) treatments can prevent gut microbiota disturbances caused by antibiotics or Clostridioides difficile infection. However, these treatments have typically been limited to restoring gut microbiota after dysbiosis, and antibiotics must be discontinued beforehand. Here, we investigated the protective effects of these treatments on gut microbiota to prevent dysbiosis during concurrent systemic ceftriaxone administration.<h4>Methods</h4>C57BL/6 mice that received intraperitoneal ceftriaxone for seven consecutive days were concomitantly treated with AC, FMT, FMT + AC, FF, or FF + AC via oral gavageScientific reportsThe effects of repeated fecal transplantation and activated charcoal treatment on gut dysbiosis induced by concurrent ceftriaxone administration in mice.PMC12015545RA-MF-52/64HEA_FF_68_079_3000_013Kumpunya SKawang KPollapong KNilaratanakul VfalseThe effects of repeated fecal transplantation and activated charcoal treatment on gut dysbiosis induced by concurrent ceftriaxone administration in mice.<h4>Background</h4>Antibiotic treatment contributes to gut microbiota dysbiosis. Previous studies have shown that fecal microbiota transplantation (FMT), fecal filtrate (FF), and activated charcoal (AC) treatments can prevent gut microbiota disturbances caused by antibiotics or Clostridioides difficile infection. However, these treatments have typically been limited to restoring gut microbiota after dysbiosis, and antibiotics must be discontinued beforehand. Here, we investigated the protective effects of these treatments on gut microbiota to prevent dysbiosis during concurrent systemic ceftriaxone administration.<h4>Methods</h4>C57BL/6 mice that received intraperitoneal ceftriaxone for seven consecutive days were concomitantly treated with AC, FMT, FMT + AC, FF, or FF + AC via oral gavage2025-01-01T00:00:00Z2025 Apr2025-07-07T03:09:58.777Z2025-07-07T03:09:58.777ZS-EPMC120155454026343810.1038/s41598-025-96701-4